QGEN
Qiagen N.V.
QGEN's fundamentals are strong: it turned 21% of its revenue into free cash flow and its operating margin rose 2 points to 25%. At 26x earnings, it's trading in line with its usual 27x. Analysts expect earnings growth.
QGEN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
QGEN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
QGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $50.10 | — |
| Cheap | 21x | $41.00 | -18% |
| Fair | 26x | $51.64 | +3.1% |
| Current | 26x | $50.10 | — |
| Expensive | 99x | $194 | +287% |
Historical ranges are pointers, not guarantees.
QGEN's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
QGEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for QGEN, with profitability holding steady.
QGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.54 | +30% |
| Q2 2026 | $1.95 | +15% |
| Q1 2026 | $1.89 | +340% |
| Q4 2025 | $1.97 | +418% |
| Q3 2025 | $1.86 | +354% |
| Q2 2025 | $1.70 | +431% |
| Q1 2025 | $0.43 | -72% |
| Q4 2024 | $0.38 | -75% |
| Q3 2024 | $0.41 | -72% |
QGEN earned $1.95 per share over the past year, up 15% from the year before.
QGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $535M | +0.3% |
| Q1 2026 | $492.3M | +1.8% |
| Q4 2025 | $540.4M | +3.7% |
| Q3 2025 | $532.6M | +6.1% |
| Q2 2025 | $533.5M | +7.5% |
| Q1 2025 | $483.5M | +5.4% |
| Q4 2024 | $521.2M | +2.4% |
| Q3 2024 | $501.9M | +5.5% |
QGEN's revenue has grown year over year for nine quarters in a row: $535M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 25% | +1.9 points |
| Q1 2026 | 24% | -0.2 points |
| Q4 2025 | 28% | +5.6 points |
| Q3 2025 | 24% | +1.9 points |
| Q2 2025 | 23% | +69 points |
| Q1 2025 | 24% | +3.2 points |
| Q4 2024 | 23% | +1.1 points |
| Q3 2024 | 22% | +1.9 points |
QGEN's operating margin was 25% last quarter, up 1.9 points from the same quarter a year ago.
QGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $157.8M | +31% |
| Q1 2026 | $53.7M | -44% |
| Q4 2025 | $117.2M | -17% |
| Q3 2025 | $119M | -14% |
| Q2 2025 | $120.6M | -5.6% |
| Q1 2025 | $95.8M | +1.2% |
| Q4 2024 | $141.9M | +43% |
| Q3 2024 | $138M | +65% |
QGEN generated $448M in free cash flow over the past year, down 9.8% from the year before.
QGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -1.1M shares |
| 1 year | -4.7% | -10.4M shares |
| 3 years | -7.1% | -15.8M shares |
| 5 years | -10% | -24.1M shares |
| Available history | -8.3% | -18.7M shares |
QGEN has 208M diluted shares, down 4.7% from a year ago, with $509M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $496.7M |
| Q4 2025 | $2.7M |
| Q3 2025 | $9.3M |
| Q2 2025 | $10.3M |
| Q1 2025 | $280.1M |
| Q4 2024 | $906,000 |
| Q3 2024 | $6.2M |
QGEN spent $509M buying back its own shares over the past year, up 71% from the year before.
QGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 2.1x | Moderate |
| Q4 2024 | 2.6x | Moderate |
| Q3 2024 | 2.6x | Moderate |
QGEN's net debt is about 1.2 years of its operating earnings (EBITDA), up from a year a year ago.
QGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.4 | Overbought |
| Stochastic | 92.8 | Overbought |
QGEN's weekly RSI is 71 (overbought) and its Stochastic is 93 (overbought).
QGEN PE vs Healthcare Sector
| Metric | QGEN | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 0.6% below |
| PE % | 44 | 29 | 15 pts above |
QGEN is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
QGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.7 | 5.1% above |
| 20 week MA | $44.4 | 13% above |
| 50 week MA | $43.5 | 15% above |
| 100 week MA | $44.1 | 14% above |
| 200 week MA | $43.9 | 14% above |
QGEN is in an uptrend: it's above all five of its weekly moving averages, and 14% above its 200-week average.
QGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.9 | $52.6 | +55% |
| 2021 | $52.6 | $55.7 | +5.8% |
| 2022 | $55.7 | $49.7 | -11% |
| 2023 | $49.7 | $43.8 | -12% |
| 2024 | $43.8 | $44.0 | +0.5% |
| 2025 | $44.0 | $47.8 | +8.6% |
| 2026 YTD | $47.8 | $50.1 | +4.9% |
QGEN has finished higher in four of the last six years. It's up 4.9% so far in 2026.